Clinical trial · Interventional
Home-based Intermittent Pneumatic Compression Therapy for Gynecologic Cancer
Home-based Intermittent Pneumatic Compression Therapy: the Impact in Chronic Leg Lymphedema in Patients Treated for Gynecologic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Investigators conducted a prospective study of cancer patients to investigate the efficacy, quality of life, satisfaction, and safety of a home-based intermittent pneumatic compression (IPC) device during the maintenance phase of lower extremity lymphedema. This device has a unique mode designed to mimic the manual lymphatic drainage (MLD) technique and thereby gently facilitate lymphatic draining of proximal extremities.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gynecologic Cancer | Malignant Female Reproductive System Neoplasm | ALIAS | 0.90 |
| Lymphedema of Leg | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| home-based intermittent pneumatic compression (IPC) device | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- home-based IPC device
- description
- Participants used a device produced by Maxstar Corp. (Gimpo, South Korea), which specializes in pneumatic compression appliance manufacture. The IPC device (UAM-9306NB) was cleared by National Institute of Medical Device Safety Information (NIDS) of Korea (approval number: 18-4745). This device consists of a six-chamber pneumatic sleeve and a gradient-sequential pneumatic pump.
- interventionNames
- Device: home-based intermittent pneumatic compression (IPC) device
Primary outcomes (1)
- measure
- Change of Inter-limb volume difference ratio
- timeFrame
- Baseline, after 1 month (4-week)
- description
- Investigators measured three leg volumes: the distal leg volume (distal volume: from the smallest circumference at the ankle (B-measure) to the calf circumference right below the knee bend (D-measure)), the whole leg volume (limb volume without the foot up to the mid-thigh region (F-measure)), and the proximal leg volume (subtraction of the distal leg volume from the whole leg volume)
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * stage 3 chronic unilateral secondary leg lymphedema * aged 20-70 years * underwent 1-2 cycle of treatment of decongestive phase with current inter-limb volume difference of more than 10% * stable limb-volume change (within 10%) during the preceding 3 months * capacity for self-maintenance care for lymphedema (multilayer limb bandaging, compression garments, and MLD) Exclusion Criteria: * bilateral leg lymphedema * current cancer metastasis * ongoing chemotherapy or radiation therapy * acute inflammation * venous thrombosis, or chronic venous insufficiency * systemic etiologies of edema * congestive heart failure * patients taking medication that influenced body fluid or electrolytes
References
Publications (0)
Data not yet available